<DOC>
	<DOCNO>NCT02697773</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy titration arm tanezumab treatment start low dose ( 2.5 mg ) increase high dose ( 5 mg ) Week 8 , compare give 2 dos tanezumab 2.5 mg 2 dos placebo . The study also evaluate safety treatment regimen .</brief_summary>
	<brief_title>Efficacy Safety Subcutaneous Tanezumab Titration Dosing Regimen Subjects With Moderate Severe Osteoarthritis Hip Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<criteria>Diagnosis Osteoarthritis knee hip confirm Xray Documented history subject try follow medication insufficient pain relief take tolerate : acetaminophen , NSAIDs either tramadol opioids Meet protocol requirement pain screen pain , physical function patient global assessment osteoarthritis baseline Willing discontinue pain medication except study medication rescue medication course study use direct per protocol Women able child must agree use 2 form contraception study Body Mass Index ( BMI ) great 39 History disease osteoarthritis shoulder , hip knee ( example , rheumatoid arthritis , gout , joint infection , osteonecrosis ) Patients xray show joint condition osteonecrosis ( dead bone ) certain type fracture Patients significant trauma surgery knee , hip shoulder within previous year Planned surgical procedure study Patients largely wholly incapacitate ( example bedridden confine wheelchair , permit little selfcare ) Patients would unwilling unable undergo joint replacement surgery one eventually become necessary Patients significant condition osteoarthritis could interfere assessment pain joint ( example fibromyalgia , lupus erythematosus ) Patients significant heart , neurological psychiatric disease Patients cancer certain skin cancer within past 5 year Patients alcohol , analgesic ( pain medication ) drug abuse within past 2 year Women pregnant , breastfeed intend become pregnant breastfeed course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>osteoarthritis knee</keyword>
	<keyword>osteoarthritis hip</keyword>
	<keyword>nerve growth factor inhibitor</keyword>
	<keyword>tanezumab</keyword>
</DOC>